A clinical-stage biotechnology company focused on developing oral immunotherapies targeting gastrointestinal diseases and immune-related conditions. Its lead programs are derived from bovine colostrum antibodies designed to prevent or treat infectious and inflammatory gut disorders, including travel...
No congressional trades have been disclosed for Imrion Technologies Inc Class A (IMRN) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
No congressional trades found for this stock.